Opus Genetics Launches First Clinical Trial for MERTK-Related Retinitis Pigmentosa Gene Therapy

Opus Genetics has officially launched its first clinical trial for an investigational gene therapy designed to treat MERTK-related retinitis pigmentosa. This rare inherited eye disease causes progressive vision loss and can eventually lead to total blindness. Currently, there are no approved medical treatments available for patients suffering from this specific condition. The new therapy, known as OPGx-MERTK, uses an adeno-associated virus to deliver a functional copy of the MERTK gene directly into retinal cells. Mutations in this gene impair the retina's ability to recycle photoreceptor components, which triggers the degeneration of the eye's light-sensing cells. By restoring the gene's function, researchers hope to halt or slow the progression of vision loss in affected individuals. The clinical trial is being conducted in Abu Dhabi through a collaborative effort involving several local and international partners. Key participants include the Department of Health – Abu Dhabi, Cleveland Clinic Abu Dhabi, and the Innovative Research Oversight and Support division of the M42 group. Cleveland Clinic Abu Dhabi will serve as the primary clinical site for the study. The hospital will utilize its specialized retinal disease clinics, surgical expertise, and advanced diagnostic imaging capabilities to support the trial's requirements. This partnership aims to combine scientific innovation with high-level clinical care to address a significant unmet medical need. George Magrath, the Chief Executive Officer of Opus Genetics, described the launch as a defining moment for both patients and the broader field of inherited retinal disease. He noted that the collaboration brings together clinical excellence and a shared commitment to addressing serious health challenges. The program is expected to move through its initial clinical development phases throughout the remainder of 2026. Researchers will closely monitor the safety and efficacy of the OPGx-MERTK therapy as the trial progresses. If successful, this treatment could provide a new pathway for patients who previously had no options to preserve their sight. The study represents a broader trend of international cooperation in testing advanced genetic therapies for rare diseases. Future results from this trial will be essential in determining the long-term viability of the treatment for patients worldwide.